Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

PURPOSE: A single-agent dose-escalating phase I and pharmacokinetic study on TSU-68, a novel multiple receptor tyrosine kinase inhibitor, was performed to determine the safety profile, maximum-tolerated dose for Japanese patients with advanced solid tumors and to define the recommended dose of phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Yutaka, Shimoyama, Tatsu, Murakami, Haruyasu, Yamamoto, Noboru, Yamada, Yasuhide, Arioka, Hitoshi, Tamura, Tomohide
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082041/
https://www.ncbi.nlm.nih.gov/pubmed/20676675
http://dx.doi.org/10.1007/s00280-010-1404-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082041/
https://www.ncbi.nlm.nih.gov/pubmed/20676675
http://dx.doi.org/10.1007/s00280-010-1404-z

Ejemplares similares